卡培他滨治疗蒽环类耐药的转移性乳腺癌

目的 研究卡倍他滨治疗既往蒽环类药物治疗失败的转移性乳腺癌患者的疗效和安全性。方法 17例具有可测量病灶的转移性乳腺癌患者接受卡培他滨（2510mg^2/天，口服14天，休息7天为一疗程）单药治疗2-6个疗程。结果 17例患者中CR1例，PR4例，SD4例和PD8例，有效率为29.3%。至疾病进展中位时间5个月（范围2-10^ 个月）。最常见的不良反应为手足综合征（64.7%)，皮肤色素沉着（58.8%)、白细胞减少（41.2%）和恶心呕吐消化道反应（17.6%），一般程度较轻，可耐受，Ⅲ度毒性反应为1例手足综合征，无IV度不良反应。应用Vitb6治疗能减轻手足综合征的症状。结论 卡培他滨治疗蒽环类药物治疗失败的转移性乳腺癌患者疗效好，不良反应少，且口服方便，对于晚期乳腺癌患者门诊治疗是一理想选择。

Xeloda(Capecitabine) in the Treatment of Metastatic Breast Cancer Patients with Anthracycline-resistance

[Purpose]To investigate the efficacy and safety of xeloda (capecitabine) in patients with advanced breast cancer who failed in previous treatment with anthracyclines. [Method] Seventeen patients with measurable lesions of advanced breast cancer received single agent xeloda of 2510 mg/m2/day for 2 weeks,every 3 weeks. Before this treatment all patients had received anthracycline. [Results]Complete response (CR) in 1 patient,partial response(PR) in four patients,stable disease(SD) in four patients and progressive disease(PD) in nine patients were obtained. Overall response rate was 29.3% . Median duration of remission was 5 (2~ 10+ ) months. The common side effects were hand-foot syndrome (64.7% ), skin pigmentation(58. 8% ), leukocytopenia(41.2% ) and nausea/vomiting(17.6% ) . Grade ffl side effects occurred in one patient with hand-foot syndrome. No grade IV toxicity was found. The symptoms of xeloda-induced hand-foot syndrome could be ameliorated by administration of VitB6 (150mg/day) . [ Conclusion ] Xeloda is a safe and promising drug for anthracycline-resistance patients with metastalic breast carcinoma.